Moxifloxacin Ophthalmic Solution Recall for Failed Impurities Specifications
Aurobindo Pharma USA Inc. is recalling Moxifloxacin Ophthalmic Solution 0.5% due to failed impurities and degradation specifications. The recall affects 115,776 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a manufacturing/quality defect (failed impurities and degradation specifications). The source text does not report any illnesses, injuries, or hospitalizations. The hazard is related to product quality specifications rather than an acute safety threat, consistent with a Moderate severity classification.
Plain-English summary
Aurobindo Pharma USA Inc. is recalling Moxifloxacin Ophthalmic Solution, USP 0.5% w/v, 3 mL bottles because the product failed to meet impurities and degradation specifications.
The recalled product is a prescription eye medication distributed nationwide under the following identifiers: NDC 65862-840-03, Lot numbers CMF210001, CMF210003, and CMF210004 with expiration date 6/2023. Approximately 115,776 bottles have been distributed.
Consumers and healthcare providers should discontinue use of affected lots and contact Aurobindo Pharma USA Inc. for replacement or refund. Patients should consult their healthcare provider if they have used this medication and have concerns about their treatment.
The recalled product
- Product
- MOXIFLOXACIN (MOXIFLOXACIN)
- Brand
- MOXIFLOXACIN
- Manufacturer
- Aurobindo Pharma USA Inc.
- Affected units
- 115,776
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot#: CMF210001
- CMF210003
- CMF210004
- Exp 6/2023
UPCs (1)
- 0365862840035
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · MOXIFLOXACIN
- LowAuroMedics Recalls Moxifloxacin Ophthalmic Solution Due to Discoloration
FDA (Drugs) · 2020-01-22
- LowLupin Recalls Moxifloxacin Ophthalmic Solution Due to Impurity Levels
FDA (Drugs) · 2019-03-06
- ModerateLupin Recalls Moxifloxacin Ophthalmic Solution Due to Stability Test Failures
FDA (Drugs) · 2019-02-20
- LowLupin Recalls Moxifloxacin Ophthalmic Solution Due to Stability Test Failure
FDA (Drugs) · 2018-08-08
Same manufacturer · Aurobindo Pharma USA Inc.
See all →- ModerateDicyclomine Hydrochloride Capsules Recalled for Empty Capsules
FDA (Drugs) · 2026-08-12
- ModerateAmazon Basic Care Acetaminophen 325 mg Tablets Recalled Due to Discoloration
FDA (Drugs) · 2025-06-25
- HighPrescription drug recall: Aurobindo Nebivolol tablets contain excess nitrosamine impurity
FDA (Drugs) · 2024-12-25
- HighPrescription Cinacalcet Tablets Recalled for N-Nitroso Impurity
FDA (Drugs) · 2024-12-11
- HighFDA Recalls Cinacalcet 30mg Tablets for N-nitroso Impurity
FDA (Drugs) · 2024-12-11
Same hazard · impurity degradation
See all →- Low
- ModerateEsomeprazole Magnesium oral suspension recalled for failed impurity specifications
FDA (Drugs) · 2025-05-28
- HighDiltiazem Hydrochloride extended-release capsules recalled due to failed quality specifications
FDA (Drugs) · 2023-02-08
- ModerateXiidra ophthalmic solution recalled for failed impurity and degradation specifications
FDA (Drugs) · 2022-06-15
- ModerateXiidra Ophthalmic Solution Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2022-06-15